• Seaport Therapeutics disclosed additional Phase 1 pharmacokinetic data for GlyphAgo ahead of an ECNP Congress poster on Oct. 11, 2026.
• Results were already generated in a completed healthy-volunteer study, with the detailed dataset to be presented in the future.
• Findings showed more reliable exposure versus unmodified agomelatine, with no meaningful food-related impact or buildup over a week of dosing.
• Program strategy targets comparable therapeutic levels at lower doses, aiming to limit liver exposure and reduce monitoring friction.
• Development has moved into Phase 2a for generalized anxiety disorder, with topline data expected in early 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seaport Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610090700BIZWIRE_USPR_____20261009_BW305659) on October 09, 2026, and is solely responsible for the information contained therein.